Ticker
ACET

Price
15.03
Stock movement down
-0.06 (-0.40%)
Company name
Adicet Bio Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
601.27M
Ent value
352.75M
Price/Sales
42.16
Price/Book
1.93
Div yield
0.27%
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
104.77%
3 year return
-39.94%
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ACET does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales42.16
Price to Book1.93
EV to Sales24.73

FINANCIALS

Per share

Loading...
Per share data
Current share count40.00M
EPS (TTM)-1.06
FCF per share (TTM)-1.38

Income statement

Loading...
Income statement data
Revenue (TTM)14.26M
Gross profit (TTM)6.02M
Operating income (TTM)-35.37M
Net income (TTM)-36.06M
EPS (TTM)-1.06
EPS (1y forward)-1.65

Margins

Loading...
Margins data
Gross margin (TTM)42.21%
Operating margin (TTM)-248.01%
Profit margin (TTM)-252.84%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash277.88M
Net receivables0.00
Total current assets281.53M
Goodwill19.46M
Intangible assets0.00
Property, plant and equipment0.00
Total assets340.45M
Accounts payable3.46M
Short/Current long term debt20.58M
Total current liabilities10.40M
Total liabilities29.37M
Shareholder's equity311.08M
Net tangible assets291.62M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-31.80M
Capital expenditures (TTM)15.02M
Free cash flow (TTM)-46.82M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-11.59%
Return on Assets-10.59%
Return on Invested Capital-11.53%
Cash Return on Invested Capital-14.97%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open15.17
Daily high15.26
Daily low14.86
Daily Volume202K
All-time high145.95
1y analyst estimate28.50
Beta-
EPS (TTM)-1.06
Dividend per share0.04
Ex-div date21 Sep 2018
Next earnings date8 Nov 2022

Downside potential

Loading...
Downside potential data
ACETS&P500
Current price drop from All-time high-89.70%-12.18%
Highest price drop-95.81%-56.47%
Date of highest drop18 Mar 20209 Mar 2009
Avg drop from high-74.99%-11.38%
Avg time to new high128 days12 days
Max time to new high1135 days1805 days
COMPANY DETAILS
ACET (Adicet Bio Inc) company logo
Marketcap
601.27M
Marketcap category
Small-cap
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Employees
86
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
September 26, 2022
REDWOOD CITY, Calif. & BOSTON, September 07, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric ant...
September 7, 2022
REDWOOD CITY, Calif. & BOSTON, August 31, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cance...
August 31, 2022
One thing we could say about the analysts on Adicet Bio, Inc. ( NASDAQ:ACET ) - they aren't optimistic, having just...
August 16, 2022
REDWOOD CITY, Calif. & BOSTON, August 10, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell ther...
August 10, 2022
REDWOOD CITY, Calif. & BOSTON, June 06, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen ...
June 6, 2022
MENLO PARK, Calif. & BOSTON, May 26, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen rec...
May 26, 2022
Shareholders in Adicet Bio, Inc. ( NASDAQ:ACET ) had a terrible week, as shares crashed 21% to US$11.83 in the week...
May 15, 2022
MENLO PARK, Calif. & BOSTON, May 12, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen rec...
May 12, 2022
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
May 12, 2022
Next page